{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02365142",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CMM-PRGF/ART"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2011-006036-23",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Clinica Universidad de Navarra, Universidad de Navarra",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma",
      "OfficialTitle": "Phase I/II. Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma(PRGF)",
      "Acronym": "CMM-PRGF/ART"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2017",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 18, 2014",
      "StudyFirstSubmitQCDate": "February 17, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 18, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 23, 2017",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 24, 2017",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Clinica Universidad de Navarra, Universidad de Navarra",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet richa plasma (PRGF) in patients with knee osteoarthritis.\n\nPatients and methods\n\nClinical trial phase I- II, randomized , multicenter , with two treatment arms and 19 patients for each group. The investigators compare the intraarticular injection of against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:\n\nGroup A: 3 intra-articular injections of platelet rich plasma (PRGF®) separated by 7 days.\nGroup B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days and one with Mesenchimal stems cells. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.\n\nIn addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:\n\nClinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\nRadiographic (baseline and 12 months from treatment): Femorotibial space.\nRadiographic using MRI (baseline and 12 months from treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.",
      "DetailedDescription": "Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet richa plasma (PRGF®) in patients with knee osteoarthritis.\n\nPatients and methods\n\nClinical trial phase I- II, randomized , multicenter , with two treatment arms and 19 patients for each group. The investigators compare the intraarticular injection of against the administration of two different doses of mesenchymal stem cells with hialuronic acid according to the following scheme:\n\nGroup A: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days.\nGroup B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7 days and one with Mesenchimal stem cell. Intra-articular injection of 100 million autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.\n\nThe autologous mesenchymal stem cells are obtained from the iliac crest under local anesthesia and sedation. They are cultured ex vivo The primary endpoint is safety and feasibility. The investigators registered the occurrence of complications and / or adverse effects during the study.\n\nIn addition the investigators assess the response to intra-articular infusion of CMM analyzing the following parameters:\n\nClinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\nRadiographic (baseline, 6 and 12 months since treatment): Femorotibial space.\nRadiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the number location of the lesions , cartilage thickness , signal intensity , subchondral bone alteration , volume and WORMS and dGEMRIC protocols.\n\nAll patients met the following inclusion and exclusion criteria:"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Knee Osteoarthritis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Knee Osteoarthritis",
          "Mesenchimal stem cell",
          "Osteoarthritis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Other",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "38",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Platelet Rich Plasma (PRGF)",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Platelet Rich plasma (PRGF)"
              ]
            }
          },
          {
            "ArmGroupLabel": "BMMSC with Platelet Rich Plasma (PRGF)",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: 100 million Bone marrow mesenchimal stem cells",
                "Biological: Platelet Rich plasma (PRGF)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "100 million Bone marrow mesenchimal stem cells",
            "InterventionDescription": "100 million Bone marrow mesenchimal stem cells with PRGF",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "BMMSC with Platelet Rich Plasma (PRGF)"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Platelet Rich plasma (PRGF)",
            "InterventionDescription": "3 injections of PRGF",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "BMMSC with Platelet Rich Plasma (PRGF)",
                "Platelet Rich Plasma (PRGF)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Baseline Visual analogue scale (VAS) Baseline Visual analogue scale (VAS)",
            "PrimaryOutcomeDescription": "Baseline Visual analogue scale (VAS) prior to the initial dose on day 1",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline value of knee injury and osteoarthritis outcome score (Koos).",
            "PrimaryOutcomeDescription": "Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).",
            "PrimaryOutcomeDescription": "Universities Osteoarthritis Index score (WOMAC).",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline SF-36 value",
            "PrimaryOutcomeDescription": "Baseline SF-36 value",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline euroquol 5D value",
            "PrimaryOutcomeDescription": "Pretreatment euroquol 5D value",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline Lequesne index",
            "PrimaryOutcomeDescription": "Prior to the intervention on day 1 Lequesne index",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Baseline femorotibial distance",
            "PrimaryOutcomeDescription": "Prior to the intervention femoritibial distance on rosenberg x-ray view",
            "PrimaryOutcomeTimeFrame": "Day 1"
          },
          {
            "PrimaryOutcomeMeasure": "Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events",
            "PrimaryOutcomeDescription": "Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events During the follow up",
            "PrimaryOutcomeTimeFrame": "Follow up (up to 12 months)"
          },
          {
            "PrimaryOutcomeMeasure": "Visual analogue scale (VAS) at 1 month",
            "PrimaryOutcomeDescription": "Visual analogue scale (VAS) at on month",
            "PrimaryOutcomeTimeFrame": "1 month"
          },
          {
            "PrimaryOutcomeMeasure": "Visual analogue scale (VAS) at 3 months",
            "PrimaryOutcomeDescription": "Visual analogue scale (VAS) at 3 months",
            "PrimaryOutcomeTimeFrame": "3 months"
          },
          {
            "PrimaryOutcomeMeasure": "Visual analogue scale (VAS) at 6 months",
            "PrimaryOutcomeDescription": "Visual analogue scale (VAS) at 6 months",
            "PrimaryOutcomeTimeFrame": "6 months"
          },
          {
            "PrimaryOutcomeMeasure": "Visual analogue scale (VAS) at 12 months",
            "PrimaryOutcomeDescription": "Visual analogue scale (VAS) at 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Value of knee injury and osteoarthritis outcome score (Koos) at 1 month",
            "PrimaryOutcomeDescription": "Value of knee injury and osteoarthritis outcome score (Koos) at 1 month",
            "PrimaryOutcomeTimeFrame": "1 month"
          },
          {
            "PrimaryOutcomeMeasure": "Value of knee injury and osteoarthritis outcome score (Koos) at 3 month",
            "PrimaryOutcomeDescription": "Value of knee injury and osteoarthritis outcome score (Koos) at 3 month",
            "PrimaryOutcomeTimeFrame": "3 Months"
          },
          {
            "PrimaryOutcomeMeasure": "Value of knee injury and osteoarthritis outcome score (Koos) at 6 month",
            "PrimaryOutcomeDescription": "Value of knee injury and osteoarthritis outcome score (Koos) at 6 month",
            "PrimaryOutcomeTimeFrame": "6 months"
          },
          {
            "PrimaryOutcomeMeasure": "Value of knee injury and osteoarthritis outcome score (Koos) at 12 months",
            "PrimaryOutcomeDescription": "Value of knee injury and osteoarthritis outcome score (Koos) at 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales and females between 40 and 80 year old\nBad results with previous hyaluronic acid injection\nDiagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology)\nJoint pain equal or greater than 2.5 points on the visual analogue scale (VAS)\nRadiological Classification: Kellgren-Lawrence scale greater or equal to 2\nBody mass index between 20 and 35 kg/m2\nAbility to follow during the study period\n\nExclusion Criteria:\n\nBilateral Osteoarthritis of the Knee requiring treatment in both knees\nPrevious diagnosis of polyarticular disease\nSevere mechanical deformation\nArthroscopy during the previous 6 months\nIntraarticular infiltration of hyaluronic acid in the last 6 months\nSystemic autoimmune rheumatic disease\nPoorly controlled diabetes mellitus\nBlood dyscrasias\nImmunosuppressive or anticoagulant treatments\nTreatment with corticosteroids in the 3 months prior to inclusion in the study\nNSAID therapy within 15 days prior to inclusion in the study\nPatients with a history of allergy to penicillin or streptomycin",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "40 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "José Lamo-Espinosa, MD",
            "OverallOfficialAffiliation": "Clinica Universidad de Navarra",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Felipe Prosper, MD, PhD",
            "OverallOfficialAffiliation": "Clínica Universidad de Navarra",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "Juan Blanco, MD; PhD",
            "OverallOfficialAffiliation": "Complejo Universitario de Salamanca",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Universitario de Salamanca",
            "LocationCity": "Salamanca",
            "LocationState": "Castilla-León",
            "LocationZip": "37007",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Departamento Cirugía Ortopédica y Traumatología. Clinica Universidad de Navarra",
            "LocationCity": "Pamplona",
            "LocationState": "Navarra",
            "LocationZip": "31008",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32948200",
            "ReferenceType": "derived",
            "ReferenceCitation": "Lamo-Espinosa JM, Blanco JF, Sánchez M, Moreno V, Granero-Moltó F, Sánchez-Guijo F, Crespo-Cullel Í, Mora G, San Vicente DD, Pompei-Fernández O, Aquerreta JD, Núñez-Córdoba JM, Vitoria Sola M, Valentí-Azcárate A, Andreu EJ, Del Consuelo Del Cañizo M, Valentí-Nin JR, Prósper F. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. J Transl Med. 2020 Sep 18;18(1):356. doi: 10.1186/s12967-020-02530-6."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "University clinic of navarre trial information",
            "SeeAlsoLinkURL": "http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010003",
            "ConditionMeshTerm": "Osteoarthritis"
          },
          {
            "ConditionMeshId": "D000020370",
            "ConditionMeshTerm": "Osteoarthritis, Knee"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001168",
            "ConditionAncestorTerm": "Arthritis"
          },
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12078",
            "ConditionBrowseLeafName": "Osteoarthritis",
            "ConditionBrowseLeafAsFound": "Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21321",
            "ConditionBrowseLeafName": "Osteoarthritis, Knee",
            "ConditionBrowseLeafAsFound": "Knee Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          }
        ]
      }
    }
  }
}